Articles By Mrinalini Dey, MD

puzzle.RA_.jpg

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials

By Mrinalini Dey, MD

Advances in the treatment of rheumatoid arthritis, particularly the treat-to-target strategy and the introduction of effective DMARDs, have improved the management of inflammation in RA. However, improved inflammatory markers do not always translate into a resolution of patients’ symptoms or improvements in functional capacity. A recent pooled analysis from the CareRA and CareRA2020 randomized controlled trials shed new light on this dissociation between biological disease control and patient-reported outcomes.

Read Article
Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

By Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

Read Article
world globe with a line of people

Health inequities in rheumatology: A central theme

By Mrinalini Dey, MD

This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.

Read Article
GCA,woman

ICYMI: SELECT-GCA suggests JAKis may be the new kid on the block

By Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
heart,CV,MI.cardia,

Addressing CV Risk in RA: Are we doing enough?

By Mrinalini Dey, MD

ORAL surveillance was a post-authorisation safety study of tofacitinib 5mg and 10mg versus TNF inhibitors, focusing on rates of adverse events, including MACE. A higher incidence of MACE was observed with the use of tofacitinib. Statins are recommended in patients with a history of atherosclerotic disease or 10 year predicted risk of MACE. But, how many patients with rheumatoid arthritis, at risk of MACE, are actually taking a statin?

Read Article
wildfire

Where there’s smoke, there’s flare: how pollution fuels RA

By Mrinalini Dey, MD

Associations between air pollution and disease activity in rheumatoid arthritis have previously been demonstrated. Abstract 0978 sought to determine the association between fire smoke and other pollutant exposures with the risk of RA and RA-associated interstitial lung disease (RA-ILD).

Read Article
Help

Health Literacy: the forgotten social determinant of health?

By Mrinalini Dey, MD

Nine out of ten adults in the USA struggle to understand basic health-related information. Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to understand health information. An increasing body of research in rheumatic diseases has sought to understand the impact of health literacy, long neglected as a social determinant of health, on clinical and non-clinical outcomes. Several abstracts at this year’s ACR Convergence focus on this topic.

Read Article
GCA,woman

SELECT-GCA suggests JAKis may be the new kid on the block

By Mrinalini Dey, MD

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.

Read Article
puzzle.RA_.jpg

Difficult-to-treat RA: are we any closer to predicting who is at risk?

By Mrinalini Dey, MD

It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.

Read Article
heart

Matters of the heart: cardiovascular disease and mortality in RA

By Mrinalini Dey, MD

Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).

Read Article
Profile picture for user Mrinalini Dey, MD
  • Mrinalini Dey, MD

  • Dr. Mrinalini Dey is a Clinical Research Fellow at the Centre for Rheumatic Diseases, King’s College London, UK. She is also a Fellow-In-Training in Rheumatology and General Internal Medicine.  She is currently pursuing a clinical PhD examining the role comorbidities and social determinants of health in outcomes in inflammatory arthritis.

    Since graduating from the University of Cambridge, in 2016, Mrinalini has pursued a clinical research career focussing on epidemiology, mixed-methods research and outcomes in inflammatory arthritis. Mrinalini sits on the Editorial Board and Digital and Social Media Committee for Rheumatology journal. She the Co-Chair of the Social Media Subcommittee of the Emerging EULAR Network (EMEUNET), as well as sitting on the EULAR People with Arthritis and Rheumatism in Europe (PARE) and Advocacy Committees. Mrinalini has a passion for teaching and science communication, and has previously been a reporter for RheumNow, as well as EULAR TV.

×